| Literature DB >> 33138840 |
Guangtao Fu1, Mengyuan Li1, Yunlian Xue2, Qingtian Li1, Zhantao Deng1, Yuanchen Ma3, Qiujian Zheng4.
Abstract
BACKGROUND: Although medical intervention of periprosthetic bone loss in the immediate postoperative period was recommended, not all the patients experienced periprosthetic bone loss after total hip arthroplasty (THA). Prediction tools that enrolled all potential risk factors to calculate an individualized prediction of postoperative periprosthetic bone loss were strongly needed for clinical decision-making.Entities:
Keywords: Gruen zones; Nomogram; Periprosthetic bone loss; Prediction tool; Total hip arthroplasty
Mesh:
Year: 2020 PMID: 33138840 PMCID: PMC7607681 DOI: 10.1186/s13018-020-02034-5
Source DB: PubMed Journal: J Orthop Surg Res ISSN: 1749-799X Impact factor: 2.359
Fig 1Seven Gruen zones used in dual-energy X-ray absorptiometrical analysis of postoperative periprosthetic BMD
Fig 2Flowchart
Demographic data
| Variables | Prevalence or average |
|---|---|
| Age (years) | 59.3 ± 10.8 |
| Male | 45.7% (195/427) |
| Married | 94.1% (402/427) |
| BMI (kg/m2) | 23.4 ± 3.8 |
| Current/former smoker | 39.6% (169/427) |
| Comorbidities | |
| Diabetes mellitus | 17.3% (74/427) |
| Hypertension | 36.3% (155/427) |
| Stroke | 6.8% (29/427) |
| Heart dysfunction | 8.7% (37/427) |
| Othersa | 17.1% (73/427) |
| Diagnosis | |
| Femoral neck fracture | 22.7% (97/427) |
| Femoral head necrosis | 49.6% (212/427) |
| Hip osteoarthritis | 17.8% (76/427) |
| Developmental dysplasia of the hip | 9.8% (42/427) |
| History of anti-osteoporosis therapy in the last year | 20.4% (87/427) |
| Preoperative systematic BMD | |
| Spine (g/cm2) | 0.881 ± 0.150 |
| Hip (g/cm2) | 0.828 ± 0.181 |
| Serum ALP (U/L) | 74.9 ± 25.6 |
| Serum calcium (mmol/L) | 2.31 ± 0.12 |
| Preoperative Harris score of the involved hip | 41.7 ± 19.9 |
| Femoral component design | |
| Straight stem | 65.1% (278/427) |
| Anatomic stem | 34.9% (149/427) |
aindicated other comorbidities including chronic obstructive pulmonary disease, pulmonary infection, dementia, Parkinson’s disease, digestive system disorders, and chronic renal failure
Main outcomes
| 1 week postoperative | 1 year postoperative | Change (1 week–1 year postoperative) | ||||
|---|---|---|---|---|---|---|
| BMD of Gruen zone 1 (g/cm2) | 427 | 0.801 (0.717, 0.891) | 427 | 0.768 (0.702, 0.842) | 427 | − 0.033 (− 0.116, 0.044) |
| BMD of Gruen zone 7 (g/cm2) | 427 | 0.889 (0.716, 1.094) | 427 | 0.807 (0.729, 0.97) | 427 | − 0.057 (− 0.157, 0.072) |
| BMD of total Gruen zones (g/cm2) | 427 | 1.44 (1.323, 1.519) | 427 | 1.395 (1.286, 1.482) | 427 | − 0.025 (− 0.09, 0.024) |
Results were presented as median (Q1, Q3)
Results of the logistic regression
| ROI 1 | ROI 7 | ROI total | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Coefficient | Standard error | Coefficient | Standard error | Coefficient | Standard error | ||||
| Age | − 0.080 | 0.035 | 0.023 | 0.033 | 0.035 | 0.346 | − 0.020 | 0.027 | 0.454 |
| Gender | − 1.518 | 0.642 | 0.018 | − 0.856 | 0.763 | 0.262 | − 0.005 | 0.588 | 0.993 |
| History of anti-osteoporosis treatment | − 1.635 | 0.848 | 0.054 | 0.497 | 0.991 | 0.616 | 0.132 | 0.763 | 0.863 |
| BMI | − 0.027 | 0.067 | 0.687 | 0.012 | 0.077 | 0.877 | − 0.144 | 0.071 | 0.042 |
| Diagnosis 1 (transform into dummy variable) | 1.687 | 1.016 | 0.097 | 0.934 | 1.006 | 0.353 | 0.805 | 0.847 | 0.342 |
| Diagnosis 2 (transform into dummy variable) | − 1.198 | 0.989 | 0.226 | − 1.949 | 1.031 | 0.059 | − 1.420 | 0.892 | 0.111 |
| Diagnosis 3 (transform into dummy variable) | − 1.220 | 0.659 | 0.064 | − 0.685 | 0.772 | 0.375 | − 1.532 | 0.658 | 0.02 |
| MNA-SF score | 0.499 | 0.364 | 0.170 | − 0.148 | 0.397 | 0.709 | − 0.097 | 0.320 | 0.762 |
| Preoperative lumbar BMD | − 2.910 | 2.819 | 0.302 | 2.483 | 3.061 | 0.417 | 0.719 | 2.512 | 0.775 |
| Preoperative hip BMD | − 1.197 | 2.604 | 0.646 | − 8.550 | 3.124 | 0.006 | − 3.161 | 2.275 | 0.165 |
| Serum ALP | − 0.017 | 0.013 | 0.180 | − 0.001 | 0.015 | 0.949 | − 0.018 | 0.012 | 0.154 |
| Serum Ca | − 4.608 | 2.922 | 0.115 | − 0.849 | 3.065 | 0.782 | 0.107 | 2.624 | 0.967 |
| Preoperative Harris score | 0.010 | 0.018 | 0.569 | 0.044 | 0.020 | 0.030 | 0.005 | 0.017 | 0.751 |
| Implant design of femoral component | 0.136 | 0.750 | 0.857 | 0.277 | 0.739 | 0.708 | 1.655 | 0.768 | 0.031 |
| BMD of ROI 1 at 1 week after THA | 7.012 | 2.715 | 0.010 | / | / | / | / | / | / |
| BMD of ROI 7 at 1 week after THA | / | / | / | 10.658 | 2.389 | < 0.001 | / | / | / |
| BMD of ROI total at 1 week after THA | / | / | / | / | / | / | 5.705 | 2.461 | 0.020 |
Fig. 3Relative importance of individual predictors within the final multivariable model for predicting bone loss in Gruen zone 1 (a), 7 (b), and total (c)
Fig. 4Nomogram predicting model for risk of postoperative bone loss in Gruen zone 1 and the prediction model performance
Fig. 5Nomogram predicting model for risk of postoperative bone loss in Gruen zone 7 and the prediction model performance measurement
Fig. 6Nomogram predicting model for risk of postoperative bone loss in Gruen zone total and the prediction model performance measurement